Increased DNA-protein cross-linking (DPX) in circulating leukocytes has been proposed as a potential biomarker for exposure and genotoxic damage caused by inhalation of certain reactive chemicals, such as hexavalent chromium [Cr(VI)]. This study was designed to determine whether ingestion of a single dose of potassium dichromate alone [Cr(VI)] or potassium dichromate fully reduced to Cr(lll) with orange juice (prior to ingestion) causes an increase in DPX of circulating leukocytes in humans. Four adult male volunteers ingested a bolus dose of 5000 |ig chromium in a 0.5 1 volume of water (10 p.p.m.), and blood samples were collected at 0, 60, 120, 180 and 240 min afterwards for analysis of DPX formation in circulating leukocytes. Results were compared to each person's own background concentration of DPX in leukocytes. Blood and urine samples were also collected for up to 2 weeks following the dose to examine the pattern of uptake and excretion of chromium. The results showed that there was no significant change in DPX observed following either Cr(VI) or Cr(TII) ingestion, even though blood and urine chromium measurements indicated systemic uptake of a substantial fraction of the ingested chromium. Since Cr(III) does not possess DPX-inducing properties while Cr(VI) does, these results suggest that the Cr(VI) was reduced to Cr(HT) intragastrically prior to absorption or that the amount of Cr(VI) absorbed into the blood was insufficient to produce DPX. These results are consistent with prior research that indicated that DPX would not occur following exposure to Cr(VI) except at very high doses.
Introduction
The development of assays capable of the detection of macromolecular adducts has revolutionized the epidemiology of cancer and chemically-induced disease. Of particular interest is the determination of DNA adducts in individuals from select populations at high risk of exposure to genotoxic chemicals due to occupational, environmental or dietary sources. A number of animal studies have shown a link between exposure to select compounds and DNA adducts. To validate in human populations what has been observed in animals, these types of investigations must address several key issues, including the specificity of the adduct for the chemical(s) of interest, reliability of the detection system under conditions used to collect and analyze the samples, presence and stability of the adduct in the tissue being sampled, and a tissue collection system that will allow reproducible detection of adducts under biologically relevant conditions. These principles can also be applied to the detection of chemically induced DNA-protein cross-links (DPXs*), which represent a major form of DNA damage (1) (2) (3) (4) . DPX detection in DNA isolated from cells has historically been based on the fractionation of DNA into protein-bound and 'free' DNA by a variety of analytical methods (5) (6) (7) (8) (9) (10) . More recently, a technique originally used to study DNA topoisomerases (11) has been modified for the purpose of rapid and sensitive detection of chemically induced DPX in intact cells and in vivo (10) .
A series of recent studies have been undertaken to determine the potential for DPX induction by heavy metal compounds (30) . The study was carried out in parallel at six different laboratories and indicated that several metal ions could initiate significant increases of DPX above background levels. These changes, however, tended to occur at concentrations of the metal ions that were incompatible with cell survival. Earlier studies have demonstrated that relatively high Cr(VI) concentrations in vitro can increase DPX (12) (13) (14) (15) (16) (17) . In addition, exposure to certain common organic compounds, e.g. formaldehyde, as well as the process of normal aging may also be important contributors to background levels of DPX in humans (16, (18) (19) (20) . Therefore, the relevance of DPX measurements as an indicator of potential human health risk from heavy metals has not been clearly established.
In this investigation we have used the technique of Zhitkovich and Costa (10) to further understand the usefulness of the DPX assay for assessing exposure to the hexavalent [Cr(VI)] or trivalent [Cr(III)] species of chromium. In the first study, Cr(VT)-spiked cell culture experiments were conducted using Burkitt's Lymphoma Cells (BLCs) to identify the acute time course of DPX formation and a possible threshold dose of Cr(VI) needed to cause a discernible increase in DPX in cultured leukocytes. The findings from the in vitro studies were used to design a protocol for evaluating DPX formation in leukocytes from human volunteers who had ingested a single bolus dose of either Cr(VI) or Cr(ni) [reduced from Cr(VI) using orange juice] in water at a concentration of 10 000 ug Cr/1 (0.5 1 ingested). The levels of total chromium in the blood and urine samples were also determined for a few days prior to and up to 2 weeks after the single dose. The objective was to correlate actual chromium concentration in vivo with the findings on Cr(VI) threshold doses for DPX formation in vitro.
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from Sigma Chemical, St Louis, MO). Log phase cells weie harvested by centrifugation at 6000 g and resuspended in fresh media containing increasing concentrations of potassium dichromate [0, 26, 104 and 260 ng Cr(VI)/l]. Cells were plated in Falcon tissue culture flasks at a cell density of IX Iff 5 cells/ml in a volume of 200 ml. From these flasks, triplicate 15 ml aliquots were removed after 1, 2, 3 and 4 h incubations. Cells were harvested at each concentration and time point by centrifugation. The cells were then rinsed three times with phosphate-buffered saline containing 1 mM EDTA (pH 7.4), then resuspended in 800 |il of this rinse buffer. Cells were lysed by addition of 100 Jil of 1% sodium dodecyl sulfate and placed on ice until all samples were collected. Cell lysates were placed at 65°C for 30 min and DNA sheared by placing the lysate in a syringe and passing it through a 21 gauge needle five times. A 100 nl aliquot of 1 M potassium chloride was added to each of the sheared lysates and they were inverted three times and placed on ice to precipitate proteins. DNA sample preparation and DNA detection were earned out as described below.
Threshold Cr(VI) concentration for DPX formation. EB V-transformed Burkitt's lymphoma cells were prepared as described above, and log phase cells were resuspended in fresh media containing increasing concentrations of potassium dichromate [0, 10.4, 26, 52, 78, 104, 260, 520 and 1040 ng Cr(Vi)/l]. One set of cells was also exposed to Cr(III) trichloride at a concentration of 1300 |ig Cr(lII)/l. Cells were plated in Falcon tissue culture flasks at a cell density of 1X10 6 cells/ml in a volume of 200 ml of the culture medium From these flasks, triplicate 15 ml aliquots were removed after a 4 h incubation. Cells were harvested and processed for determination of DPX as described above.
Assay for measuring DNA-protein cross-links. White blood cells were isolated from whole blood using Ficoll-Hypaque gradient centrifugation. The white blood cell samples were rinsed three times in 10 ml of phosphate-buffered (pH 7.4) normal saline containing 0.1 mM EDTA to remove chromium or other potential contaminants from the exterior of the cells. This is an important step, as failure to remove any Cr(III) exterior to the cells can result in artifactual DPX formation during work-up of the raw DNA. Following the saline washes, the cells were lysed in a 0.5% SDS solution as previously described (10) . The samples were frozen at -70°C for 3-4 days in lysed form. DNA-protein cross-links induced by chromate have been observed to be stable for at least 2 weeks when stored under these conditions (Kuykendall 1995, unpublished data) . Cell samples were thawed at 37°C and the DNA was sheared by passing the cell lysates five times through a 21 gauge needle. The lysates were expelled into a tube by applying medium pressure but extensive foaming was always avoided. A 0.5 ml aliquot of 100 mM KC1, 20 mM Tris-HCl, pH 7.5 (KCl-Tris) was then added. The contents were mixed by vortexing the tube for 5 s at maximal speed and the tubes were then heated for 30 min at 65°C. Samples were removed from the water bath, inverted three times, then placed on ice for 5 min to form potassium dodecyl sulfate precipitates. The precipitate was collected by centrifugation at 6000 g for 5 min at 4°C. The supernatant was removed and the pellet was resuspended in KCl-Tris by brief vortexing at the highest setting. The samples were again heated at 65°C for 10 min and the washing steps described above, as well as the heating steps, were repeated two more times. Protein-linked DNA was released from the final K-SDS precipitate by treatment with 0.2 mg/ml proteinase K in 0.5 ml solution containing 100 mM KCl-Tris and 10 mM EDTA.
The samples were then incubated at 50°C for 3 h. A 50 |il aliquot of 4 mg/ml bovine serum albumin was added to each tube and the samples were placed on ice. The tubes were centrifuged at 12 000 g for 10 min at 4°C and the supernatant was taken to determine the quantity of DNA. It was important at this point to avoid disturbing the potassium dodecyl sulfate pellet while aspirating the supernatant, since SDS interferes with the Hoechst 33258 assay.
DNA was detected using Hoechst 33258 by the method of Labarca and Paigen (21) . DNA standards were prepared at concentrations of 100, 200, 500, 2000 and 5000 ng/ml. Precaution was taken to avoid exposure to light at this point, and the samples were placed in the dark for 10 min. Fluorescence was assessed by excitation at 365 nm and the emitted light was measured at 450-460 nm. A bovine serum albumin tube was used as the standard blank.
Human exposure protocol and participants
Absorption and elimination rates of chromium were evaluated after ingestion of single doses of two different chromium mixtures: (1) potassium dichromate in water, and (2) potassium dichromate reduced completely to Cr(III) in orange juice and then diluted in water. These experiments were conducted 30 days apart. In each experiment, 5000 ng Cr were ingested in 0.5 1 of deionized water (0.5 1 of 10.0 p.p.m. Cr), with the entire dose being swallowed by each volunteer within 2 min.
A Human Use Committee comprised of three board-certified occupational physicians and one board-certified toxicologist (each was a university faculty member) reviewed the study protocol prior to initiation. The committee concluded that the study design was adequate to satisfy the objectives and that the doses would not pose a health risk to the participants. The committee concluded that the participants were properly informed of the reported adverse health effects associated with exposure to chromium.
Six healthy, male, Caucasian volunteers (ages 21-66) weighing 160-220 pounds were included in the single dose experiments. Two of the volunteers received no dose of chromium and served as negative control subjects [H10, age 35, in the Cr(III) study and H6, age 42, in the Cr(VI) study]. One of the subjects (H8) was a current smoker of approximately 6 to 12 cigarettes per day. All other volunteers never smoked. Prior to participation in the study, all individuals completed a consent form, as well as a questionnaire regarding basic physiological and medical information. No medical conditions were reported by the volunteers that would preclude their participation in the study, e.g. chromium allergy or gastrointestinal disease or dysfunction. Prior to and following ingestion of the chromium dose in each experiment, each volunteer had clinical screening tests performed, including a complete blood count (CBC), clinical chemistries (SMA-20) and urinalysis. The purpose of these clinical tests was to identify any significant changes in hematology, blood chemistries or urinalysis that might have been due to exposure to Cr(VI).
Diet was not controlled in this study. The participants followed their normal dietary food and liquid intake practices with the exception that they were prohibited from ingesting vitamin supplements containing vitamin C or chromium. Because many foods contain varying amounts of chromium (22), a detailed log of each participant's beverage, food or dietary supplement intake was maintained throughout the duration of the study. The participants also recorded any physical activity (exercise) other than normal daily activity that may affect urinary creatinine measurements.
Sample collection and analyses
Potassium dichromate (K2O2O7) was used as the source of soluble Cr(VI). The Cr(VI) mixture was prepared for each participant by pipetting an aliquot from a 1000 |ig/l standard solution (Fluka Chemical Corp., Ronkonkoma, NY) into a 0.5 1 volume of deionized water. The Cr(VI)-orange juice solution [i.e. Cr(VI) reduced to Cr(IH) and probable organic complexes] was prepared by adding the same aliquot to approximately 300 ml of single strength orange juice from concentrate that had been strained of pulp solids prior to mixing. This solution was then brought to a 0.5 1 volume using deionized water. All drinking water samples were assayed for both Cr(VI) and total chromium concentrations at MBT Environmental Laboratories (Rancho Cordova, CA) using EPA Methods 7196 and 218.2, respectively. Water containing 10.0 mg Cr(VI)/l (p.p.m.) was noted to have a bright yellow color.
In both experiments, each urine void was collected in separate containers starting on day 1 (beginning with the first morning void) through the last day of study (including the last void before bedtime or until midnight). Samples were stored at refrigerator temperatures and packed in coolers with ice packs for delivery to the National Medical Services (NMS) Laboratory (Willow Grove, PA).
The participants were assigned (according to their geographic location) to a medical clinic where the blood samples were collected for analysis. Blood samples were drawn, centrifuged, and separated for analysis of plasma and RBCs at designated intervals. The sample vials used in this study (glass vacutainer tubes with royal blue tops made by Becton Dickinson or Sherwood Medical) contained an ethylenediamine tetra-acetate (EDTA) anticoagulant and a guaranteed low metals content. The negligible concentration of Cr in the tubes was validated through separate testing (contribution <0.4 |ig Cr/1; D.Paustenbach el al. 1996, in preparation) The labeled blood samples were sent to the laboratory via overnight delivery.
DPX measurements were performed only on the day the dose was ingested. A registered phlebotomist performed all blood draws from the participants on the dose day, including pre-dose (zero time), and at 60, 120, 180 and 240 min following ingestion of the dose. An aliquot of 15 ml of blood was collected from each volunteer at these time points. The blood was stabilized with EDTA, centrifuged at 3000 g for 3 min, and the white blood cell layer pipetted into a separate polyethylene tube. The DPX assay was then performed in triplicate as described above.
Total chromium analyses. All urine samples were analyzed for total chromium, total urine volume, specific gravity and creatinine at NMS Laboratories. An Atago Uncon-N urine specific gravity refractometer (NSG Precision Cells; Farmingdale, NY) was used to determine urine specific gravities. An alkaline picrate procedure (Instrumentation Laboratory Monarch 2000, Instrumentation Laboratory, Lexington, MA) was used to measure urinary creatinine. Urinary creatinine was used to correct for urine volume differences between samples due to variable fluid intakes by the participants. The concentration of total chromium was determined using a PE-4100 ZL graphite furnace atomic absorption spectrometer (AAS) according to EPA Method 218.2. The limit of detection was 0.5 ng Cr/1 unne. The concentrations of total chromium in the samples were then obtained from a calibration curve of total chromium in urine. The DPX results of both the Cr(III) and Cr(VI) ingestion studies were evaluated using ANOVA with repeated measures (with Bonferroni 'post hoc testing') to determine whether the difference at each time point after the exposure varied significantly from the control values. The significance level was set at P < 0.05.
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Results
Cultured lymphocyte study results
Acute time course of DPX formation in leukocytes. Data generated in the time course experiments are presented in Figure 1 . The untreated (control) cultured Burkitt's lymphoma cells exhibited an average background DPX level of 2.3 to 2.7% of DNA in the cross-linked fraction, which is consistent with other assays performed previously using this cell line in our laboratory. The incubation of these cells with increasing concentrations of Cr(VI) yielded a dose-and time-dependent increase in DPX levels, which became statistically significant (P < 0.05) at 4 h in 260 ng Cr(VI)/l, and at 3 h in 1040 and 2600 (lg Cr(VI)/l concentrations as potassium dichromate. After 4 h of incubation with potassium dichromate, cultures containing 260, 1040 and 2600 |ig Cr(VI)/l exhibited increases of DPX levels equivalent to 1.3-, 2.0-and 2.9-fold that of control cultures assayed at that time point. From these data we suggest that die method may be valid for the detection of DPX in lymphoid tissues exposed to low concentrations of Cr(VI) over a 3-4 h time period. In contrast, 1300 (ig Cr(III) as CrCl^ did not increase the level of DNA-protein cross-links compared to concurrent controls (data not shown).
Threshold Cr(VI) concentration for increased DPX formation in leukocytes (in vitro
)
Human ingestion study of chromium uptake and excretion
In this study, volunteers ingested 0.5 1 of 10 000 ug Cr/1 solution as potassium dichromate [Cr(VI)] in water or potassium dichromate reduced to Cr(IIT) in orange juice (i.e. 5000 \ig Cr). The 0.5 1 volume was consumed by each volunteer within a 2 min period in the morning between 9:30 and 11:45 to simulate ingestion on a relatively empty stomach. None of the volunteers had eaten for at least 2-3 h prior to dosing to maximize the opportunity for uptake of Cr(VI) into the blood. Blood and urine chromium levels were measured for 1-3 days prior to testing, at 10 designated time points within 8 h of the single dose ingestion, and at 1 to 3 day intervals up to 14 days after the dose. None of the volunteers exhibited clinical abnormalities or unusual fluctuations in the SMA-20, complete blood count, or urinalysis when the pre-and post-dosing measurements were compared (data not shown).
Urinary excretion. Administration of potassium dichromate reduced in orange juice (presumably to Cr(ffl)-organic complexes and Cr(III) ions) resulted in an average bioavailability of 0.60% and elevated urinary Cr excretion for 4 to 5 days (Table I) . On average, 91% (27 (ig) of the bioavailable dose was excreted in urine during the first 4 days. As shown in Table I , peak urinary chromium concentrations averaged 24 |ig Cr/g creatinine (range: 18 to 36 (ig Cr/g creatinine). Urinary chromium levels returned to pre-study (background) levels by J.R.Kuykcndall et al. (Table I) . One volunteer, H5, was an apparent outlier in the Cr(VI) study as he had a 5-fold higher urinary chromium excretion within 4 days and a 7-fold higher peak chromium concentration in urine compared to the average for the other three volunteers. On average, 80% (283 \ig) of the bioavailable dose was excreted in urine during the first 4 days. Peak concentrations of Cr in urine averaged 209 (ig Cr/g creatinine (range: 29 to 585 (ig Cr/g creatinine; Table I ). Only one subject, H4, had definitely returned to pre-study background levels prior to the end of the study (day 10 post-dose); however, by day 14 post-dose all subjects except the apparent outlier described above had returned to their typical background concentrations for urine (i.e. ND to 2.0 |ig Cr/g creatinine). The average urinary excretion half-life was calculated to be 39 h (range: 36-41). More specific data on the profile of chromium in urine for each individual after Cr(VI) ingestion are published elsewhere (23) .
Tbble L
Bioavailability and tissue chromium measurements following ingestion of 5 mg Cr(Vl) in water or reduced to Cr
Chromium concentrations in plasma and erythrocytes (RBCs).
Administration of potassium dichromate reduced to Crijn) in orange juice resulted in an average chromium concentration of 2.1 ng/\ in plasma and 5.5 u.g/1 in RBCs (Table I) . Peak plasma and RBC levels were observed generally between 15 and 120 min after the dose. Both RBC and plasma chromium levels remained elevated slightly above pre-dose background concentrations in each volunteer for 1 to 3 days after the dose.
Single dose administration of 10 000 |ig Cr(VI)/l resulted in concurrent elevations in plasma and RBC chromium content in all volunteers. Peak plasma and RBC concentrations occurred and reached an apparent plateau for all subjects within 90 min after dosing, with an average concentration of 25 fig Cr/1 in plasma and 18 u.g/1 in RBCs (Table I) chromium content by the end of this monitoring period (up to 14 days post-administration). More specific data on the profile of chromium in blood for each individual after Cr(VI) ingestion is published elsewhere (23) . DPX measurements in human leukocytes following chromium ingestion. The data on DPX levels in leukocytes of human volunteers ingesting Cr(III) (reduced from Cr(VI) with orange juice) and Cr(VI) in water are presented in Figures 3 and 4 , respectively. ANOVA with repeated measures (with Bonferroni 'post hoc testing') was used to determine if there were any statistically significant changes (P < 0.05) in the DPX levels of study participants before versus after ingestion of the chromium dose, and for exposed versus control subjects. There were no significant changes in the DPX levels in leukocytes isolated from the negative control volunteers in each experiment at any time point (1 to 4 h) compared to the time zero value, suggesting that the assay should be free from time pointdependent error which could lead to significant differences at each sample isolation time. Further, there were no statistically significant changes in DPX levels for any of the individuals ingesting the dose of either Cr(III) or Cr(VI) when comparing pre-dose to post-dose measurements (i.e. using each person's pre-dose DPX level as the control value).
Discussion
To our knowledge, this study represents the first effort to evaluate DNA-protein cross-linking (DPX) in humans under conditions of known (controlled) dosing. The data indicate that human exposure to a bolus dose of 5000 (ig Cr(VI) or Cr(VI) reduced to Cr(III) does not produce a change in the concentration of DPX in circulating leukocytes. Changes in DPX were absent even in volunteers who absorbed a substantial fraction of the administered dose (up to 18% based on urine measurements). These findings provide some insight regarding both the reduction capacity of the human gastrointestinal tract, as well as the potential in vivo mutagenicity and carcinogenicity of Cr(VI) when ingested at plausible doses in drinking water. Our in vitro observations regarding the time course and threshold dose of Cr(VI) in cultured leukocytes suggest that the in vivo concentrations of Cr(VI) in the blood of the human volunteers studied here were probably below the apparent threshold for DPX induction (-26 to 52 |ig Cr/1). The study was designed to evaluate relatively 'worst case' exposure scenarios, i.e. (1) chromium was ingested on a relatively empty stomach, at least 2 h from the last meal [limiting the influence of gastric juices and pH to reduce Cr(Vl)]; (2) 0.5 1 was ingested within a brief time period (2 min) to simulate the exposure of a very thirsty person; and (3) the Cr(VI) concentration (10 000 ng/1) had a bright yellow color and hence regular ingestion seems unlikely to occur. Despite these conditions, no increase in DPX was observed in the volunteers. None of the volunteers experienced any symptoms of toxicity, e.g. clinical screening of urine, blood chemistry and blood counts were all unchanged. Upon questioning, no gastrointestinal distress was reported by any volunteer. This is consistent with subchronic and chronic drinking water studies where ingestion of 25 000 to 137 000 |ig Cr(VI)/l by rodents did not result in any observable adverse effects (24) (25) (26) .
Our inability to find increases in DPX levels in peripheral leukocytes in humans is not surprising. Although it has been found that Cr(VI) accumulates in leukocytes both in vitro and in vivo (27) , DPX formation has not been found to occur after oral ingestion of Cr(VI), even at high doses in animals. Indeed, although chromium could be detected in the blood cells of rats exposed to 100 000 and 200 000 |ig Cr(VI)/l in drinking water for 3 and 6 weeks, no DPX could be detected in splenic leukocytes using either monoclonal antibodies or alkaline elution techniques (14) . This was interpreted to mean that the chromium levels required to induce DPX in leukocytes in vitro may not be reached in leukocytes in vivo after oral absorption of high doses of chromium.
Preliminary experiments in vitro were also performed to evaluate the time course and possible tissue concentration thresholds for induction of increased DPX in cultured leukocytes. The time-course experiments showed that addition of Cr(VI) to the culture media results in a significant increase in DPX of Burkitt's lymphoma cells within 3 to 4 h, and that this response is dose-dependent. The in vitro dose threshold experiments indicated that no discernible or statistically significant increases in DPX occur in this test system when concentrations of Cr(VI) at or below 26 \igf\ are added to the medium. Concentrations of Cr(in) chloride at 1300 (ig/1 failed to cause an increase in DPX in our test system.
In a previous study (23), we examined chromium uptake and elimination following repeated oral doses of CrCVI) in drinking water. We concluded that only a small fraction of the total chromium uptake (if any) was likely attributable to Cr(VI) based on the blood and urine profiles, which were consistent with uptake and distribution in the trivalent state. In a followup study (34) , we examined the pharmacokinetics of chromium in humans following ingestion of single, bolus doses of (1) potassium dichromate in water; (2) potassium dichromate reduced completely to Cr(III) in orange juice and then diluted in water; and (3) chromium (III) chloride in water. Based on comparisons of the half-life, bioavailability, and blood and urine profiles for each of these compounds, we concluded that ingestion of Cr(VI) in water at concentrations =£ 10 000 |ig/l results in predominant chromium uptake in the form of Cr(III) complexes. This is consistent with the findings in the current study since increases in DPX were not observed following ingestion of Cr(VI).
It is notable that background blood plasma concentrations of total chromium in our volunteers averaged approximately 1.2 jj.g/1 and ranged up to nearly 60 (i.g/1 within hours after ingesting the bolus dose of Cr(VI). Although we lack enough information to perform a direct quantitative analysis between the in vitro and the in vivo findings on chromium (VI and III) concentrations, it appears that the absorbed chromium dose for certain volunteers in the Cr(VI) experiment might have been sufficient to expect an increased rate of DPX if one ignores the other reducing elements of the blood (e.g. red blood cells and plasma). However, we believe these data and other published observations (28, 29) suggest that the Cr(VI) reducing potential of the upper gastrointestinal tract and the blood are probably more than sufficient to prevent appreciable absorption and systemic distribution of chromium in the hexavalent form at plausible concentrations in drinking water (e.g. <2000 fig/1 , a concentration at which the yellow color of Cr(VI) in water is discernible to most people). In a recent study, no increase in DPX was detected in a human volunteer following ingestion of 2 1 of 2000 \ig Cr(VI)/l per day for 15 days (data not shown). Further, no evidence of in vivo genotoxicity of Cr(VI) in drinking water at concentrations ranging from 1000 to 20 000 (j.g/1 was detected using two standard genotoxicity assays: (1) the mouse bone marrow micronucleus assay and (2) the in vivo-in vitro rat hepatocyte unscheduled DNA synthesis (UDS) assay (30) . These data further support the conclusion that no appreciable Cr(VI) enters the bloodstream at these exposure concentrations.
Leukocyte samples from the ingestion of Cr(VI) and of Cr(IU) were analyzed for DPX as separate groups, since they were carried out about one month apart. It is critical to treat each sample in a particular phase of a study as identically as possible. This is why the leukocyte samples were lysed after isolation and stored on dry-ice until they could be sheared and fractionated as a group. This was done to control for variations that may result from differences in sample handling. It is readily apparent that intra-individual variations in DPX may be present and statistically significant. However, due to the nature of the assay, individuals may have different background levels (time zero), which may be the result of dietary and/or lifestyle differences in these persons. Another point is the 'assay to assay' differences in DPX levels that may be apparent. For instance, seemingly insignificant differences in work-up of samples from the separate assays may result in slight, but significant, changes in DPX levels for the whole group or even the same individual. However, these differences should not affect the interpretation of the data with respect to the control level carried out at the initiation of each study, assuming that the samples were worked-up at the same time under the same conditions.
Only one other published study has utilized a similar technique to assay DPX levels in humans potentially exposed to chromium (31) . These investigators reported a small but statistically significant increase in DPX levels in leukocytes isolated from blood samples taken from welders, compared to a control group from the same geographic location. The implications of this study are unclear due to apparent deficiencies inherent to the study design by Costa et al. (31) . First, it is not possible to determine which of many potential crosslinking agents may be responsible for the small increase in DPX among the welders. Such workers are certainly exposed to both chromium and nickel, which are known to cause DPX (18), but also to a variety of combustion products possibly including formaldehyde, a relatively potent inducer of DPX (16) . Second, smoking status of the workers was apparently not controlled in the study; mainstream smoke also contains formaldehyde and a wide variety of other reactive and clastogenic agents (32) . Third, the interindividual variability of the results as indicated by coefficients of variation is broad for both the control (5-40%) and the exposed (3-59%) groups. Such variability may imply imprecision of the DPX assay, poor classification of individuals as to their exposure to DPXinducing chemicals, and/or some other poorly characterized influence on DPX formation or repair that may vary from one person to the next. And fourth, the authors apparently did not determine the exposure concentrations or range of plausible 1976 doses for chromium or the other potential DPX-inducing chemicals in the workplace. Consequently, it is unclear whether it is biologically plausible to expect an increase in DPX due to chromium at the doses received by welders. In summary, the findings of Costa et al. (31) regarding DPX increases in welders are difficult to interpret with respect to specific chemical causation.
Conclusions
In conclusion, this study demonstrates that oral administration of Cr(VI) or Cr(VI) reduced with orange juice at 10 000 ^g Cr/1 in drinking water results in no change in the background rate of DNA-protein cross-links in peripheral leukocytes. These findings and the pharmacokinetic profile of absorbed chromium in blood and urine of the exposed subjects indicate predominant reduction of Cr(VI) in the stomach and small intestine followed by systemic uptake, distribution and excretion as Cr(rn). Administration of both Cr(VI) and Cr(III) at 10 000 |ig Cr/1 can cause temporary elevations in RBC and plasma chromium levels, with more extended excretion times probably influenced by Cr(VI) reduction, binding to organic ligands, and distribution to different pharmacokinetic storage compartments in the body as compared to inorganic Cr(III). The available toxicity information on chromium compounds in animals and the apparent lack of substantial Cr(VI) uptake into the bloodstream after ingestion of bolus doses at 10 000 (i.g Cr(VI)/l suggests that such oral exposures in humans are not hazardous.
